ORCHPHARMA — Orchid Pharma Share Price
Last trade - 00:00- IN₹42.67bn
- IN₹41.84bn
- IN₹8.19bn
- 73
- 15
- 31
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.24 | ||
| PEG Ratio (f) | 0.84 | ||
| EPS Growth (f) | 50.96% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.35 | ||
| Price to Tang. Book | 3.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.55 | ||
| EV to EBITDA | 33.76 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.27% | ||
| Return on Equity | 9.51% | ||
| Operating Margin | 9.42% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 4,838.02 | 4,500.6 | 5,595.57 | 6,658.98 | 8,193.68 | 9,288 | 13,560.67 | 6.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +494.16 | -0.6 | +50.96 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
Directors
- S. Mani CEX
- V. Vijayendran CEX
- P. Deshpande EVP
- J. Surya Kumar SVP
- U. P. Senthil Kumar SVP
- V. Padalkar SVP
- B. Gopalan CSO (62)
- Nikita K CCO
- Deepak Nayyar VPR
- Sampath Parthasarathy VPR
- Manish Dhanuka MDR
- A. Suresh Babu OTH
- Edna Braganza OTH
- M. Rangesh OTH
- Soundara Kumar DRC (65)
- Rabinarayan Panda DRC
- Sundaram Yuvaraj DRC
- Mudit Tandon NID
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 1992
- Public Since
- September 6th, 1993
- No. of Shareholders
- 37,450
- No. of Employees
- 872
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 50,719,105
- Address
- Orchid Towers, CHENNAI, 600034
- Web
- https://www.orchidpharma.com/
- Phone
- +91 4425211000
- Auditors
- Singhi & Co
Latest News for ORCHPHARMA
Upcoming Events for ORCHPHARMA
Q4 2025 Orchid Pharma Ltd Earnings Release
Q1 2026 Orchid Pharma Ltd Earnings Release
Orchid Pharma Ltd Annual Shareholders Meeting
Similar to ORCHPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 22:28 UTC, shares in Orchid Pharma are trading at IN₹808.55. This share price information is delayed by 15 minutes.
Shares in Orchid Pharma last closed at IN₹808.55 and the price had moved by -25.98% over the past 365 days. In terms of relative price strength the Orchid Pharma share price has underperformed the S&P BSE 100 Index by -30.28% over the past year.
The overall consensus recommendation for Orchid Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOrchid Pharma does not currently pay a dividend.
Orchid Pharma does not currently pay a dividend.
Orchid Pharma does not currently pay a dividend.
To buy shares in Orchid Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹808.55, shares in Orchid Pharma had a market capitalisation of IN₹42.67bn.
Here are the trading details for Orchid Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ORCHPHARMA
Based on an overall assessment of its quality, value and momentum Orchid Pharma is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Orchid Pharma is IN₹1,444.17. That is 78.61% above the last closing price of IN₹808.55.
Analysts covering Orchid Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹18.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orchid Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -34.2%.
As of the last closing price of IN₹808.55, shares in Orchid Pharma were trading -39.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Orchid Pharma PE ratio based on its reported earnings over the past 12 months is 28.24. The shares last closed at IN₹808.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Orchid Pharma's management team is headed by:
- S. Mani - CEX
- V. Vijayendran - CEX
- P. Deshpande - EVP
- J. Surya Kumar - SVP
- U. P. Senthil Kumar - SVP
- V. Padalkar - SVP
- B. Gopalan - CSO
- Nikita K - CCO
- Deepak Nayyar - VPR
- Sampath Parthasarathy - VPR
- Manish Dhanuka - MDR
- A. Suresh Babu - OTH
- Edna Braganza - OTH
- M. Rangesh - OTH
- Soundara Kumar - DRC
- Rabinarayan Panda - DRC
- Sundaram Yuvaraj - DRC
- Mudit Tandon - NID